Bauer, Todd
Cho, Byong Chul
Heist, Rebecca
Bazhenova, Lyudmila
Werner, Theresa
Goel, Sanjay
Kim, Dong-Wan
Adkins, Douglas
Carvajal, Richard D.
Alva, Ajjai
Eaton, Keith
Wang, Judy
Liu, Yong
Yan, Xiaohong
Christensen, Jamie
Neuteboom, Saskia
Chao, Richard
Pant, Shubham
Funding for this research was provided by:
Mirati Therapeutics, Inc.
Article History
Received: 20 April 2022
Accepted: 16 June 2022
First Online: 29 June 2022
Declarations
:
: This study was approved by an institutional review board at each participating site and was conducted in accordance with Good Clinical Practice guidelines, defined by the International Conference on Harmonisation. All patients provided written informed consent.
: TMB declares Consulting or advisory role: Guardant Health, Loxo, Pfizer, Exelixis, Blueprint Medicines, Foundation Medicine, Bayer, AstraZeneca; Consulting or advisory role to institution: Ignyta, Moderna Therapeutics, Pfizer; Speakers’ bureau: Bayer, Bristol-Myers Squibb, Eli Lilly; Research funding to institution: Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, Inc., MedImmune, Abbvie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Genentech/Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Moderna Therapeutics, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Loxo, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Onyx, Phosplatin Therapeutics, Foundation Medicine, ARMO BioSciences; Travel, accommodation, expenses: Astellas Pharma, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Eli Lilly, Merck, Novartis, Pharmacyclics, Sysmex, Pfizer BCC declares Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD, Abbvie, Medpacto, GIInnovation, Eli Lilly, Blueprint Medicines, Interpark Bio Convergence Corp.; Consulting role: Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Bristol Myers Squibb, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint Medicines; Stock ownership: TheraCanVac Inc., Gencurix Inc., Bridgebio Therapeutics, KANAPH Therapeutic Inc., Cyrus Therapeutics, Interpark Bio Convergence Corp.; Scientific Advisory Board: KANAPH Therapeutic Inc., Brigebio Therapeutics, Cyrus Therapeutics, Guardant Health, Joseah BIO; Board of director: Gencurix Inc., Interpark Bio Convergence Corp.; Royalty: Champions Oncology; Founder: DAAN Biotherapeutics. RH declares Consulting: Abbvie, Novartis, EMD Serono, Daichii Sankyo; Research funding to institution, not to self: Abbvie, Agios, Corvus, Daichii Sankyo, Exelixis, Mirati Therapeutics, Inc., Novartis, Eli Lilly, Turning Point. LB declares Data Monitoring Committee: ORIC; Advisory board: Turning Point Therapeutics, Daichi, Bristol Myers Squibb, Janssen, Merck, Regeneron, Bayer, Takeda, Boehringer Ingleheim, Novartis, Genentech and Sanofi; Scientific committee: Neuvogen; Research funding to institution: Beyondspring. TLW declares research funding to institution from: AbbVie, AstraZeneca, Clovis Oncology, Genmab, GlaxoSmithKline-Tesaro, Mersana, Repare, Roche-Genentech. SG was funded by Mirati Therapeutics, Inc. to conduct this trial (to the institution). DWK declares research funding to institution from: Alpha Biopharma, Amgen, AstraZeneca/MedImmune, Boehringer Ingelheim, Bridge BioTherapeutics, Chong Keun Dang, Daiichi-Sankyo, GlaxoSmithKline, Hanmi, Janssen, Merus, Mirati Therapeutics, Inc., MSD, Novartis, ONO Pharmaceutical, Pfizer, Roche/Genentech, Takeda, Turning Point Therapeutics, Xcovery, Yuhan; Travel and accommodation support for advisory board meeting attendance from: Amgen, Daiichi-Sankyo. DA declares Consulting or scientific advisory board support: Vaccinex, Merck, Blueprint Medicines, Boehringer Ingelheim, Cue Biopharma, Kura Oncology, Eisai, Exelixus, twoXAR, Immunitas, Natco Pharma, TargImmune Therapeutics, and Xilio; Institutional research support: Vaccinex, Pfizer, Eli Lilly, Merck, Celgene/Bristol Myers Squibb, Novartis, AstraZeneca, Atara Bio, Blueprint Medicine, Celldex, Enzychem, Kura, Exelixis, Innate, Sensei, Debiopharm International, ISA Therapeutics, Gilead Sciences, BeiGene, Roche, Hookpia Biotech, Adlai Nortye USA, Rubius Therapeutics, Epizyme, and Matrix Biomed. RDC declares Consulting: Alkermes, Bristol Myers Squibb, Castle Biosciences, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento Therapeutics, Trisalus; Clinical/Scientific Advisory Boards: Aura Biosciences, Chimeron, Rgenix; Research Funding to Columbia University: Amgen, Astellis, AstraZeneca, Bristol Myers Squibb, Corvus, Ideaya, Immunocore, Iovance, Merck, Mirati Therapeutics, Inc., Novartis, Pfizer, Plexxikon, Regeneron, Roche/Genentech. AA declares to be an advisory board member/consultant for: Merck, Sharp & Dohme Corp, Bristol Myers Squibb, AstraZeneca, Genentech, Roche, Pfizer, Progenics, Prometheus; Travel/Accommodations/Expenses: Merck Sharp & Dohme Corp, Bristol Myers Squibb; Research funding through institution: Merck Sharp & Dohme Corp, AstraZeneca, Bristol Myers Squibb, Astellas, Seattle Genetics, Genentech, Pfizer, Progenics, Prometheus, Eli Lilly, ASCO, Celgene, Harpoon Therapeutics. KDE declares research support for clinical trials from Mirati Therapeutics, Inc. JSW declares research funding to institution from: Agenus, AstraZeneca, AstraZeneca/MedImmune, Bicycle therapeutics, BioNTech, Boehringer Ingelheim, Celgene, CicloMed, Clovis Oncology, Cyteir, Daiichi Sankyo, Genentech/Roche, GlaxoSmithKline, H3 Biomedicine, Hutchison MediPharma, Ignyta, Jacobio, Janssen Research & Development, Klus Pharma, Kymab, Loxo, LSK BioPharma, Macrogenics, Merck, Moderna Therapeutics, Phoenix Pharmaceuticals, Prelude Therapeutics, QiLu Pharmaceutical, Revolution Medicines, Ribon Therapeutics, Syndax, Stemline Therapeutics, Taiho Pharmaceutical, Tesaro, TopAlliance BioSciences Inc, Xencor, Artios, Erasca, Inc., immuno-Gen, Cullinan Oncology, Immuno-Onc, Bayer Health, Biosplice, Zymeworks, BioTheryX, TeneoBio, Nurix, IgM Biosciences, Aevi Genomic Medicine, PureTech, StingThera, Forty Seven, Treadwell Therapeutics, MabSpace Biosciences, Novartis, Olema Oncology, Seven and Eight Biopharmaceuticals, ORIC Pharmaceuticals, Relay Therapeutics, Black Diamond Therapeutics. YL is a full-time employee of Mirati Therapeutics, Inc. XY is a full-time employee of Mirati Therapeutics, Inc. and owns Mirati stocks. JGC is an employee, shareholder and executive officer at Mirati Therapeutics, Inc. STCN is a former employee of Mirati Therapeutics, Inc. and owns Mirati stocks. RCC is a full-time employee of Mirati Therapeutics, Inc. SP declares Clinical Trials Research (paid to institution) from: Arcus, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Holy Stone Healthcare Co., Tyme, Ipsen, Mirati Therapeutics, Inc., Novartis, Xencor, Astellas, Janssen; Advisory Board/Consultant: 4D Pharma, Xencor, Ipsen, Zymeworks, Amal Therapeutics, Novartis.